Michael Szarek, PhD, on Treatment Advances With Tivozanib for RCC Going Forward

Video
Conference|ASCO Genitourinary Cancers Symposium

The expert from SUNY Downstate Medical Center highlighted areas in which he believes treatment for renal cell carcinoma will advance.

In an interview with CancerNetwork®, Michael Szarek, PhD, of the SUNY Downstate Medical Center, spoke about where he believes renal cell carcinoma treatment will advance in the coming years.

Transcription:

Tivozanib [Fotivda] is a [tyrosine kinase inhibitor]. There are a lot of different drugs that are approved for renal cell carcinoma. One of the future [prospects] is obviously for the PD-1 class to move into renal cell carcinoma more and more. Combinations with PD-1 [inhibitors] is one area. Hopefully, if tivozanib is approved, then I think other sponsors and perhaps the sponsor of the drug itself will look into combining it with other agents including [PD-1 inhibitors]. So that’s one likely future avenue for the treatment of renal cell carcinoma.

Recent Videos
For example, you have a belt of certain diseases or genetic disorders that you come across, such as sickle cell disease or thalassemia, that are more prevalent in these areas.
Talent shortages in the manufacturing and administration of cellular therapies are problems that must be addressed at the level of each country.
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
Point-of-care manufacturing, scalable manufacturing, and bringing the cost down [can help].
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss presentations at ESMO 2025 that may impact bladder, kidney, and prostate cancer care.
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
A novel cancer database may assist patients determine what clinical trials they are eligible to enroll on and identify the next best steps for treatment.
Receiving information regarding tumor-associated antigens or mutational statuses from biopsies may help treatment selection in GI malignancies.
Related Content
ESMO Congress 2025 included a variety of presentations that may change the treatment paradigm in lung cancer, breast cancer, and other types of disease.

ESMO 2025: The Top 10 Takeaways That May Shift Oncology Practice

Russ Conroy
October 24th 2025
Article

ESMO Congress 2025 included a variety of presentations that may change the treatment paradigm in lung cancer, breast cancer, and other types of disease.

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

Exploring the ESMO 2025 Presentations That May Shift GU Oncology

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
October 16th 2025
Podcast

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

Sacituzumab govitecan plus pembrolizumab reduced symptom burden and improved functioning across multiple domains in the KEYNOTE-D19 study.

Patient-Reported Outcomes Support Sacituzumab Govitecan Combo in TNBC

Kristie L. Kahl
October 23rd 2025
Article

Sacituzumab govitecan plus pembrolizumab reduced symptom burden and improved functioning across multiple domains in the KEYNOTE-D19 study.

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025
Podcast

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Buparlisib/Chemo Does Not Improve OS in PD-1 Recurrent Head and Neck Cancer

Buparlisib/Chemo Does Not Improve OS in PD-1 Recurrent Head and Neck Cancer

Gina Mauro
October 21st 2025
Article

The BURAN trial revealed no overall survival benefit for buparlisib and paclitaxel in recurrent head and neck cancer, despite some response rate improvements.

• Nivolumab plus ipilimumab continued to show clinically meaningful PFS improvement over nivolumab alone in MSI-H/dMMR mCRC.

Nivolumab/Ipilimumab Maintain PFS Benefit vs Nivolumab Monotherapy in MSI-H/dMMR CRC

Kristie L. Kahl
October 20th 2025
Article

With a median follow-up of 50.1 months, nivolumab plus ipilimumab achieved a median PFS of not reached compared with 60.8 months with nivolumab monotherapy in this CRC population.